These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15090834)

  • 21. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
    Rizzardi GP; Tambussi G; Bart PA; Chapuis AG; Lazzarin A; Pantaleo G
    AIDS; 2000 Oct; 14(15):2257-63. PubMed ID: 11089613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study.
    Rasmussen LD; Dybdal M; Gerstoft J; Kronborg G; Larsen CS; Pedersen C; Pedersen G; Jensen J; Pedersen L; Sørensen HT; Obel N
    HIV Med; 2011 Apr; 12(4):202-10. PubMed ID: 20726905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide population-based cohort study.
    Larsen MV; Omland LH; Gerstoft J; Larsen CS; Jensen J; Obel N; Kronborg G
    Addiction; 2010 Mar; 105(3):529-35. PubMed ID: 20402997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.
    Murphy EL; Collier AC; Kalish LA; Assmann SF; Para MF; Flanigan TP; Kumar PN; Mintz L; Wallach FR; Nemo GJ;
    Ann Intern Med; 2001 Jul; 135(1):17-26. PubMed ID: 11434728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors, CD4 long-term evolution and mortality of HIV-infected patients who persistently maintain low CD4 counts, despite virological response to HAART.
    Pacheco YM; Jarrín I; Del Amo J; Moreno S; Iribarren JA; Viciana P; Parra J; Gomez-Sirvent JL; Gutierrez F; Blanco JR; Vidal F; Leal M;
    Curr HIV Res; 2009 Nov; 7(6):612-9. PubMed ID: 19929797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
    Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
    PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.
    Anastos K; Barrón Y; Cohen MH; Greenblatt RM; Minkoff H; Levine A; Young M; Gange SJ
    Ann Intern Med; 2004 Feb; 140(4):256-64. PubMed ID: 14970148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/microL.
    Moore DM; Hogg RS; Yip B; Craib K; Wood E; Montaner JS
    HIV Med; 2006 Sep; 7(6):383-8. PubMed ID: 16903983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?
    Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
    AIDS; 2003 Mar; 17(5):711-20. PubMed ID: 12646794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.
    Sterling TR; Chaisson RE; Moore RD
    AIDS; 2001 Nov; 15(17):2251-7. PubMed ID: 11698698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A search for optimal criteria in initiating antiretroviral therapy in chronic human immunodeficiency virus infection focusing on CD4 count and HIV RNA.
    Ormaasen V; Bruun JN; Sandvik L; Holberg-Petersen M; Gaarder PI
    Scand J Infect Dis; 2002; 34(12):910-7. PubMed ID: 12587624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals.
    Lohse N; Obel N; Kronborg G; Laursen A; Pedersen C; Larsen CS; Kvinesdal B; Sørensen HT; Gerstoft J
    AIDS; 2005 May; 19(8):815-22. PubMed ID: 15867496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy.
    Yacisin K; Maida I; Ríos MJ; Soriano V; Núñez M
    AIDS Res Hum Retroviruses; 2008 Jul; 24(7):935-40. PubMed ID: 18593347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study.
    Dragsted UB; Mocroft A; Vella S; Viard JP; Hansen AB; Panos G; Mercey D; Machala L; Horban A; Lundgren JD;
    J Infect Dis; 2004 Jul; 190(1):148-55. PubMed ID: 15195254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.
    Tarwater PM; Gallant JE; Mellors JW; Gore ME; Phair JP; Detels R; Margolick JB; Muñoz A
    AIDS; 2004 Dec; 18(18):2419-23. PubMed ID: 15622318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.